BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 3161209)

  • 1. The plasma inhibitors of plasminogen activator, studied by a zymographic technique.
    Booth NA; Anderson JA; Bennett B
    Thromb Res; 1985 May; 38(3):261-7. PubMed ID: 3161209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet release protein which inhibits plasminogen activators.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1985 Jul; 38(7):825-30. PubMed ID: 3926830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
    Walker B; Elmore DT
    Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and partial characterization of a specific plasminogen activator inhibitor in human chondrocyte cultures.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Biochem; 1988 Dec; 104(6):960-7. PubMed ID: 3149640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on human activators of plasminogen.
    Mackie M; Booth NA; Bennett B
    Br J Haematol; 1981 Jan; 47(1):77-90. PubMed ID: 6449216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
    Zhang X; Chaudhry A; Chintala SK
    Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions.
    Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
    Ann Otol Rhinol Laryngol; 1985; 94(3):293-6. PubMed ID: 3925865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human articular cartilage contains an inhibitor of plasminogen activator.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Rheumatol; 1988 Jul; 15(7):1138-43. PubMed ID: 3139880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
    Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
    Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretion of plasminogen activator inhibitor by cultured human epidermal cells.
    Hashimoto K; Nishioka K; Katayama I; Yoshikawa K
    Br J Dermatol; 1986 Aug; 115(2):133-8. PubMed ID: 3091060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification of epidermal plasminogen activator inhibitor.
    Hibino T; Izaki S; Izaki M
    FEBS Lett; 1986 Nov; 208(2):273-7. PubMed ID: 3096778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the polyphenols of cider on plasmin and plasminogen activators.
    Ogston D; Lea AG; Langhorne P; Wilson SB
    Br J Haematol; 1985 Aug; 60(4):705-13. PubMed ID: 3161536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
    Andreasen PA; Nielsen LS; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
    J Biol Chem; 1986 Jun; 261(17):7644-51. PubMed ID: 3086313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
    Stephens RW; Fordham CJ; Doe WF
    Eur J Cancer Clin Oncol; 1987 Feb; 23(2):213-22. PubMed ID: 2965017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma.
    Clemmensen I; Thorsen S; Müllertz S
    Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
    Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    Vassalli JD; Belin D
    FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.